Population diversity in batches of the varicella Oka vaccine

Vaccine

Volumn 29, Issue 17, 2011, Pages 3293-3298

  Kanda, R K ^a   Quinlivan, M L ^a   Gershon, A A ^c   Nichols, R A ^b   Breuer, J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c NewYork Presbyterian Hospital   (United States)

Author keywords

Batch; Comparative sequence alignment; Genetic diversity; Oka vaccine; Pyrosequencing; Variation; Varicella zoster virus

Indexed keywords

CHICKENPOX VACCINE; LIVE VACCINE;

ALLELE; ARTICLE; GENE FREQUENCY; GENE LOCUS; GENETIC VARIABILITY; MOLECULAR EVOLUTION; NONHUMAN; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VARICELLA ZOSTER VIRUS; VIRUS STRAIN;

CHICKENPOX VACCINE; GENE FREQUENCY; GENETIC VARIATION; HERPESVIRUS 3, HUMAN; HUMANS; POLYMERASE CHAIN REACTION; RNA, VIRAL; SEQUENCE ANALYSIS, DNA;

EID: 79954571937     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.02.021     Document Type: Article

References (18)

1. Lau Y.L., Vessey S.J., Chan I.S., Lee T.L., Huang L.M., Lee C.Y., et al. A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX in healthy children. Vaccine 2002, 20(23-24):2942-2949.
2. Sharrar R.G., LaRussa P., Galea S.A., Steinberg S.P., Sweet A.R., Keatley R.M., et al. The postmarketing safety profile of varicella vaccine. Vaccine 2000, 19(7-8):916-923.
3. Galea S.A., Sweet A., Beninger P., Steinberg S.P., Larussa P.S., Gershon A.A., et al. The safety profile of varicella vaccine: a 10-year review. J Infect Dis 2008, 197(Suppl. 2):S165-S169. Review.
4. Goulleret N., Mauvisseau E., Essevaz-Roulet M., Quinlivan M., Breuer J. Safety profile of live varicella virus vaccine (Oka/Merck): five-year results of the European Varicella Zoster Virus Identification Program (EU VZVIP). Vaccine 2010, 28(36):5878-5882.
5. Quinlivan M., Breuer J. Molecular studies of Varicella zoster virus. Rev Med Virol 2006, 16(July-August (4)):225-250. Review.
6. Takahashi M., Otsuka T., Okuno Y., Asano Y., Yazaki T. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974, 2(7892):1288-1290.
7. Gomi Y., Sunamachi H., Mori Y., Nagaike K., Takahashi M., Yamanishi K. Comparison of the complete DNA sequences of the Oka varicella vaccine and its parental virus. J Virol 2002, 76(November (22)):11447-11459.
8. Gomi Y., Imagawa T., Takahashi M., Yamanishi K. Oka varicella vaccine is distinguishable from its parental virus in DNA sequence of open reading frame 62 and its transactivation activity. J Med Virol 2000, 61(August (4)):497-503.
9. Quinlivan M.A., Gershon A.A., Nichols R.A., La Russa P., Steinberg S.P., Breuer J. Vaccine Oka varicella-zoster virus genotypes are monomorphic in single vesicles and polymorphic in respiratory tract secretions. J Infect Dis 2006, 193(7):927-930.
10. Loparev V.N., Rubtcova E., Seward J.F., Levin M.J., Schmid D.S. DNA sequence variability in isolates recovered from patients with postvaccination rash or herpes zoster caused by Oka varicella vaccine. J Infect Dis 2007, 195(4):502-510.
11. Tillieux S.L., Halsey W.S., Thomas E.S., Voycik J.J., Sathe G.M., Vassilev V. Complete DNA sequences of two oka strain varicella-zoster virus genomes. J Virol 2008, 82(November (22)):11023-11044.
12. Quinlivan M.L., Gershon A.A., Steinberg S.P., Breuer J. Rashes occurring after immunization with a mixture of viruses in the Oka vaccine are derived from single clones of virus. J Infect Dis 2004, 190(4):793-796.
13. Quinlivan M.L., Gershon A.A., Al Bassam M.M., Steinberg S.P., LaRussa P., Nichols R.A., et al. Natural selection for rash-forming genotypes of the varicella-zoster vaccine virus detected within immunized human hosts. Proc Natl Acad Sci USA 2007, 104(1):208-212.
14. D'Hondt E., Berge E., Colinet G., Duchene M., Peetermans J. Production and quality control of the Oka-strain live varicella vaccine. Postgrad Med J 1985, 61(Suppl. 4):53-56.
15. Frey C.R., Sharp M.A., Min A.S., Schmid D.S., Loparev V., Arvin A.M. Identification of CD8+ T cell epitopes in the immediate early 62 protein (IE62) of varicella-zoster virus, and evaluation of frequency of CD8+ T cell response to IE62, by use of IE62 peptides after varicella vaccination. J Infect Dis 2003, 188(1):40-52.
16. Mattocks C., Tarpey P., Bobrow M. Whittaker, comparative sequence analysis (CSA): a new sequence-based method for the identification and characterization of mutations in DNA. J Hum Mutat 2000, 16(November (5)):437-443.
17. Zerboni L., Hinchliffe S., Sommer M.H., Ito H., Besser J., Stamatis S., et al. Analysis of varicella zoster virus attenuation by evaluation of chimeric parent Oka/vaccine Oka recombinant viruses in skin xenografts in the SCIDhu mouse model. Virology 2005, 332(1):337-346.
18. Spackova M., Wiese-Posselt M., Dehnert M., Matysiak-Klose D., Heininger U., Siedler A. Comparative varicella vaccine effectiveness during outbreaks in day-care centres. Vaccine 2010, 28(3):686-691. Erratum in: Vaccine. 2010 May 7;28(21):3754.